BoomRay secures exclusive global license with Novartis for a novel radioligand therapy, boosting Novartis' oncology pipeline
Executive summary: BoomRay Pharmaceuticals entered into an exclusive global license agreement with Novartis for a novel radioligand therapy asset. The agreement expands Novartis' radioligand pipeline and provides BoomRay with upfront financing and potential milestone revenues, validating its technology in the precision oncology market.
Who is involved: BoomRay Pharmaceuticals Co., Ltd. and Novartis.
Likely next: The parties will proceed with preclinical and clinical development steps, with milestone payments triggered upon achieving predefined development, regulatory and commercial goals.
On September 22, 2026, BoomRay Pharmaceuticals announced an exclusive global licensing agreement with Novartis for a new radioligand therapy asset. The deal grants Novartis worldwide development and commercialization rights, while BoomRay receives an upfront payment and is eligible for milestone payments based on development, regulatory and sales targets. Radioligand therapies are a rapidly growing segment of precision oncology, and the partnership reflects Novartis' strategy to expand its targeted radiotherapy offerings.
What's next — scenarios
Base: agreement proceeds as planned with milestone payments triggered (50%)
Novartis advances the asset into clinical trials, BoomRay receives staged payments supporting its RLT pipeline.
- Positive IND-enabling studies completed by Q2 2027
- Novartis files IND with FDA by Q4 2027
- No major safety signals observed in preclinical tox
Upside: early clinical data shows strong efficacy, leading to accelerated development and additional indications (30%)
Fast-track designation possible, potentially boosting peak sales estimates and prompting Novartis to consider broader licensing or co‑development.
- Phase 1 trial demonstrates >50% tumor response rate by mid‑2028
- EMA grants PRIME status in 2028
- Novartis announces expansion to a second cancer indication
Downside: regulatory or safety concerns delay or halt the program (20%)
Development is put on hold, BoomRay may not receive further milestones, and Novartis may seek alternative radioligand partners.
- FDA places clinical hold due to unexpected toxicity in 2027
- EMA raises concerns about radiation dosimetry in 2028
- BoomRay fails to meet a preclinical milestone, pausing payment schedule
Timeline
- — BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset (PR Newswire)
Analysis — what this means
Sectors affected
- radioligand therapy
- precision oncology
- biopharmaceutical manufacturing
Key entities
Sources
- BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset — PR Newswire
Related cases
- Novartis trial failure triggers sector-wide selloff in biopharma stocks
- Novartis reports positive trial results for a new multiple sclerosis therapy with reduced liver toxicity
- Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
- Novartis delivered Q2 2026 sales growth and advanced its drug pipeline while reaffirming its full-year financial guidance
- Novartis reports Q2 sales growth, pipeline advances, and reaffirms full‑year 2026 guidance